Evidence map›Paper›PMID 40542219›Full record

ArticleCommunications biology2025

Molecular features defining the efficiency of bioPROTACs.

Dorothea Winkelvoß, David Vukovic, Anna-Carina Hänny, Luca Riermeier, Anto Udovcic, Jonas Kolibius, Annemarie Honegger, Peer R E Mittl, Erich Michel, Simon Hansen and 1 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Writing the CRBN degron.Nature chemical biology · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dorothea Winkelvoß *Department of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0008-6697-4621
David Vukovic *Department of Biochemistry, University of Zurich, Zurich, Switzerland.
Anna-Carina HännyDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0004-3386-4208
Luca RiermeierDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0007-9869-589X
Anto UdovcicDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0007-8017-085X
Jonas KolibiusDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-0545-3773
Annemarie HoneggerDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-3378-3967
Peer R E MittlDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-3348-3147
Erich MichelDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-5252-5429
Simon HansenDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.
Andreas PlückthunDepartment of Biochemistry, University of Zurich, Zurich, Switzerland. plueckthun@bioc.uzh.ch.ORCID http://orcid.org/0000-0003-4191-5306

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030_192689
6 · The paper itself

Abstract

BioPROTACs consist of a target-binding unit and a component of the ubiquitin-proteasome system. However, the specific biophysical features influencing their effectiveness are poorly understood. We investigated the design principles defining the target-binding moiety of bioPROTACs. We used our recently developed assay for accurately measuring degradation rates, based on microinjection and live-cell microscopy, independent of other confounding factors like biosynthesis and transport. We used a very efficient UPS interaction domain from CHIP E3 ligase, and 9 different well-characterized DARPins to test degradation of the proof-of-principle target eGFP. All but two DARPins work well in this context, one sterically preventing E2 binding in the complex, the other overlapping with the target ubiquitination epitope. Affinity and thermodynamic stability of the binders had only a modest role. BioPROTACs constructed in this way were able to degrade eGFP catalytically. DARPins by themselves could also accelerate degradation of bound GFP, using other cellular E3 systems, but in a non-catalytic manner. The most important factor for efficient degradation by a bioPROTAC in trans is the correct orientation of the complex for target ubiquitination and presentation to the proteasome, still to be determined empirically. The strategies developed here show an efficient pathway to characterize and optimize such systems.

Indexed as

Proteasome Endopeptidase ComplexUbiquitinUbiquitin-Protein LigasesGreen Fluorescent ProteinsHumansProtein BindingProteolysisUbiquitinationenhanced green fluorescent proteinGreen Fluorescent ProteinsProteasome Endopeptidase ComplexUbiquitinUbiquitin-Protein Ligases

Identifiers

PMID40542219
PMCPMC12181330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.